Mereo BioPharma Group PLC ADR (MREO) — Cash Flow-to-Debt Ratio
Mereo BioPharma Group PLC ADR (MREO) has a Cash Flow-to-Debt Ratio of -1.04x as of September 2025, meaning its operating cash flow of $-7.31 Million could theoretically repay -1% of its total liabilities ($7.00 Million) in one year. See MREO FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Mereo BioPharma Group PLC ADR Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Mereo BioPharma Group PLC ADR across 10 annual periods. Also explore Mereo BioPharma Group PLC ADR equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Mereo BioPharma Group PLC ADR (2015–2024)
Year-by-year debt coverage analysis for Mereo BioPharma Group PLC ADR. For market capitalisation and broader financial context, see MREO stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.13x | $-32.83 Million | $15.42 Million | ▼ -60.8% |
| 2023 | -1.32x | $-21.13 Million | $15.96 Million | ▲ +29.5% |
| 2022 | -1.88x | $-48.82 Million | $26.01 Million | ▼ -1279.0% |
| 2021 | -0.14x | $-7.07 Million | $51.95 Million | ▲ +62.5% |
| 2020 | -0.36x | $-38.62 Million | $106.55 Million | ▲ +63.2% |
| 2019 | -0.98x | $-60.22 Million | $61.19 Million | ▼ -46.8% |
| 2018 | -0.67x | $-23.14 Million | $34.51 Million | ▲ +29.4% |
| 2017 | -0.95x | $-32.15 Million | $33.85 Million | ▲ +74.0% |
| 2016 | -3.65x | $-27.40 Million | $7.51 Million | ▼ -213.6% |
| 2015 | -1.16x | $-6.70 Million | $5.76 Million | — |